{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for m root_polymer_monomers_monomerSubstance_refPname in Monomer Substance Name (approximate match)
Status:
US Approved Rx
(2020)
Source:
ANDA209599
(2020)
Source URL:
First approved in 1964
Class:
POLYMER
Status:
Excipient
Source:
9.2mg ORAL TABLET, EXTENDED RELEASE
Source URL:
Class:
POLYMER
Status:
Other
Class:
POLYMER
Status:
Other
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
M020
(2024)
Source URL:
First approved in 2022
Source:
21 CFR 352
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 343
(2021)
Source URL:
First approved in 2021
Source:
21 CFR 343
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
NDA212608
(2020)
Source URL:
First approved in 2020
Source:
NDA212608
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2017)
Source URL:
First approved in 2017
Source:
21 CFR 348
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2016)
Source URL:
First approved in 2016
Source:
21 CFR 352
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
ANDA200491
(2012)
Source URL:
First approved in 2012
Source:
ANDA200491
Source URL:
Class:
POLYMER
